Feds Oppose Hospitals’ Intervention in Three More Pharma 340B Lawsuits

The federal government has asked three more federal judges to not let hospital groups intervene in drug manufacturers' lawsuits challenging HHS's 340B contract pharmacy requirements. | Shutterstock
The federal government has asked federal district judges in Indianapolis, Delaware, and New Jersey to deny hospital groups’ requests for active roles in drug manufacturers’ Eli Lilly’s, AstraZeneca’s, and Sanofi’s lawsuits against the government over its 340B contract pharmacy requirements.
Read More »

HRSA Takes Step Forward on 340B Dispute Resolution Petitions

HRSA this week notified 340B covered entities that it had finished reviewing their administrative dispute resolution petitions for completeness, and determined that they were complete. | Shutterstock
The federal government on Tuesday declared 340B administrative dispute resolution (ADR) petitions by covered entities against drug manufacturers AstraZeneca, Eli Lilly, and Sanofi to be “complete,” a sign that claims against two of the three companies—AstraZeneca and Sanofi—are ready for
Read More »

Feds Oppose Hospitals’ Motion to Intervene in Novo Nordisk’s 340B Lawsuit

The federal government said this week that hospital groups should not be allowed to participate as third parties in Novo Nordisk's lawsuit against the government over enforcement of its 340B contract pharmacy requirements.
The federal government on Monday strongly objected to letting six hospital groups participate as third parties in drug manufacturer Novo Nordisk’s lawsuit challenging the government’s 340B contract pharmacy requirements.

Please Login or Become a Paid Subscriber

Read More »

340B Dispute Resolution Injunction Is Having Ripple Effects

The federal judge considering drug manufacturer Sanofi’s motion for protection from 340B dispute resolution proceedings wants to hear more about a different court's recent decision to grant Eli Lilly such protection.
The federal judge considering drug manufacturer Sanofi’s motion for protection from 340B dispute resolution proceedings asked the company and the federal government last Wednesday to brief her on a different federal judge’s order the day before granting drug company Eli
Read More »

Federal Judge To Get Status Report Today from Ryan White Clinics and Government

HIV/AIDS clinics' and community health centers' lawsuits to force HHS to act against drug manufacturers denying 340B pricing are both being heard in federal district court in Washington, D.C.
Ryan White Clinics for 340B Access (RWC-340B) and the federal government have a deadline today to report to a federal judge about whether to continue the stay in the group’s suit to force the government to act against drug manufacturers
Read More »

Injunction in Lilly Case Could Cause HHS to Re-Issue 340B Dispute Resolution Rule

Drug manufacturer Eli Lilly said it is pleased with a court's injunction yesterday stopping 340B dispute resolution proceedings against it over its denials of 340B pricing on contract pharmacy drugs. | Shutterstock
A federal judge’s decision to temporarily shield drug manufacturer Eli Lilly from the 340B program’s administrative dispute resolution (ADR) process could cause the government to issue 340B ADR regulations all over again, health care attorneys say.
Read More »

Sanofi Calls 340B ADR System “a Faux Judicial Process”

Drug manufacturer Sanofi, in its latest filing in federal district court in New Jersey, called the new 340B administrative resolution system a false judicial process designed to punish drug companies.
Drug manufacturer Sanofi on Monday struck back at the U.S. Justice Department (DOJ) for opposing its Feb. 2 motion in a federal lawsuit requesting an injunction against the 340B program’s new administrative dispute resolution (ADR) process.
Read More »

Hospitals Want Role in Three More Pharma Lawsuits Over 340B Contract Pharmacy

Hospital groups want to intervene in opposition to three more drug manufacturers' lawsuits against the federal government over 340B contract pharmacy requirements.
Hospital groups that recently filed a motion to intervene in opposition to drug manufacturer Eli Lilly’s lawsuit against the federal government over 340B contract pharmacy requirements also are trying to intervene in similar suits against the government by manufacturers AstraZeneca,
Read More »

DOJ Opposes Sanofi’s Move to Head Off 340B Dispute Resolution in Contract Pharmacy Battle

For the second time in a matter of days, the U.S. Justice Department has asked a court to reject drug company motions to halt the 340B administrative dispute resolution system.
The U.S. Justice Department (DOJ) has slammed a second drug manufacturer’s motion before a federal court to block implementation of the 340B program’s new administrative dispute resolution (ADR) process.

Please Login or Become a Paid Subscriber

Read More »
Generic selectors
Exact matches only
Search in title
Search in content